High Tide - CEO, Raj Grover.
CEO, Raj Grover.
Source: LinkedIn.
  • High Tide (HITI) has confirmed that its Canna Cabana retail cannabis stores in Ontario will begin selling Cabana Cannabis Co. products this fall
  • Products include shatter, THC gummies, pre-rolls, and full-spectrum multicannabinoid tinctures and softgels 
  •  The licensed producers with whom High Tide has entered into white label agreements have received approval from the Ontario Cannabis Store to list their initial Cabana Cannabis Co. branded products
  • High Tide is a retail-focused cannabis company with brick-and-mortar as well as global e-commerce assets
  • High Tide (HITI) opened trading at $2.59

High Tide (HITI) has confirmed that its Canna Cabana retail cannabis stores in Ontario will begin selling Cabana Cannabis Co. branded products this fall.

This confirmation comes from the producers that High Tide has entered into white label agreements with receiving approval from the Ontario Cannabis Store to list their Cabana Cannabis Co. branded products as part of the OCS’ Fall Product Call for 2022.

The initial lineup of Cabana Cannabis Co. products, and the licensed producers who have received OCS approval to sell the products, are as follows:

  • Heritage Cannabis Holdings (CNSX: CANN): Cabana Cannabis Co. Pink Hawaiian shatter, available in 1-gram packages.
  • Loosh Brands: Cabana Cannabis Co. THC gummies, available in both Sunset Punch and Clementine Cream flavours, and sold in packages of two soft chews at 5 milligrams of THC each.
  • Candre Cannabis Inc.: Cabana Cannabis Co. Apricot Jelly pre-rolls, available in 1.5-gram packages which will include three pre-rolls at 0.5 grams each.
  • Emprise Canada: Cabana Cannabis Co. full-spectrum multicannabinoid (including CBD, CBN, CBG, CBC, and Delta-9 THC) oil and softgels. The oil will be available in 30 millilitre containers at a concentration of 12 milligrams per millilitre for each of the five listed cannabinoids, while the softgels will be available in packages of 120 softgels, each containing 3 milligrams of each of the five listed cannabinoids.

All products in the OCS’ Fall Product Call are expected to become available for retail sales in October or November 2022.

Raj Grover, President and Chief Executive Officer of High Tide, commented on the news.

“I am very pleased to announce that we have a confirmed timeline to begin sales of Cabana Cannabis Co. products in Ontario, which is Canada’s largest provincial market for cannabis. By drawing on the latest insights into consumer preferences from our Cabanalytics data and working with our contracted licensed producers through white label agreements, we are introducing a lineup of the greatest hits of premium and competitively-priced products that we know will be well-received by our customers.”

“As I stated last week upon the initial launch of the Cabana Cannabis Co. lineup in Saskatchewan, bringing these newly-developed SKUs to market in multiple provinces is only the first step in High Tide’s white label strategy. We intend to continue leveraging our Cabanalytics data to significantly expand the Cabana Cannabis Co. catalogue moving forward, through white label contracts with licensed producers. Over the long-term, we intend to have 20-30 per cent of our total bricks-and-mortar sales come from the expanded Cabana Cannabis Co. product lineup, allowing us to enhance our bricks-and-mortar retail margins while also directly serving the preferences and needs of our customers. I once again want to applaud the forward-thinking decision of the AGCO to allow for white label partnerships in Ontario, which will enhance the customer experience while also allowing for greater product differentiation, benefitting retailers large and small,” added Mr. Grover.

High Tide is a retail-focused cannabis company with brick-and-mortar as well as global e-commerce assets.

High Tide (HITI) opened trading at C$2.59.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.